Do chaperones selectively recognize pathological vs physiological protein conformations?
Title: J-protein co-chaperone repertoire enables selective recognition of pathogenic conformers
Mechanism: DNAJB6 (HSP40 family) exhibits selective anti-amyloid activity distinct from DNAJB2, which favors protein refolding. The differential interaction kinetics between specific J-proteins and HSP70 create a "client code" that preferentially engages with the structured β-sheetrich cores of pathological aggregates versus the more helical, solvent-exposed intermediates in normal folding trajectories.
Target: DNAJB6/DNAJB2 ratio; HSP70 (HSPA8/HSPA1A) client complexes
Supporting Evidence:
- DNAJB6 specifically suppresses polyglutamine aggregation (PMID: 17993627)
- DNAJB2 selectively disaggregates stress granules (PMID: 34541823)
- HSF1 activation increases anti-aggregation J-protein expression (PMID: 28017844)
Predicted Experiment: CRISPRi screens targeting 50+ J-protein family members in iPSC-derived neurons with α-synuclein PFF seeding; measure pathologic inclusions vs. cell viability to map selectivity landscape.
Confidence: 0.65
---
Title: CK2-mediated HSP90α phosphorylation switches client discrimination toward disease conformers
Mechanism: Casein kinase 2 (CK2) phosphorylates HSP90α at T115 and S226, allosterically remodeling the ATP-binding pocket and N-terminal domain interface. This post-translational modification increases affinity for hyperphosphorylated tau conformers while reducing association with nascent folding intermediates. CK2 inhibitors (CX-4945) would restore broader client selectivity at the cost of reduced engagement with pathologic conformers.
Target: CK2-HSP90α axis; phosphorylation-dependent client recognition
Supporting Evidence:
- CK2 phosphorylates tau at multiple AD-relevant sites (PMID: 29374255)
- HSP90 inhibitors show disease-modifying effects in tauopathy models (PMID: 30258079)
- N-terminal HSP90 phosphorylation correlates with neurodegeneration (PMID: 33741461)
Predicted Experiment: Isothermal titration calorimetry comparing phosphorylated vs. non-phosphorylated HSP90α binding to recombinant tau pre-formed fibrils vs. monomeric tau; validate with phospho-mimetic T115E/S226E mutants.
Confidence: 0.55
---
Title: Exposed amyloidogenic segments ( residues with high β-sheet propensity) serve as HSP70 recognition codes
Mechanism: Pathological conformers expose "aggregation nucleation" sequences—typically 5-15 residue hydrophobic stretches—that are buried in native folds. HSP70 binds these segments with higher affinity than their native counterparts due to chronic exposure in misfolded states. The thermodynamic preference for these segments explains apparent "selectivity" for pathogenic species over transient native-state fluctuations.
Target: HSPA8/HSPA1A substrate-binding domain; aggregation-prone sequences in TDP-43, α-synuclein, tau, huntingtin
Supporting Evidence:
- HSP70 preferentially binds α-synuclein at N-terminal and NAC regions (PMID: 29463785)
- J-domain proteins enhance HSP70 affinity for amyloid cores (PMID: 33902342)
- HSP70 suppresses early nucleation steps in aggregation kinetics (PMID: 33427873)
Predicted Experiment: Hydrogen-deuterium exchange mass spectrometry mapping HSP70 binding sites on α-synuclein monomer vs. PFF; compare wild-type to A53T mutant to quantify conformational selectivity.
Confidence: 0.70
---
Title: CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformers for proteasomal degradation
Mechanism: The co-chaperone CHIP (STUB1) bridges HSP70/HSP90 to the proteasome. Pathological oligomers uniquely engage HSP70 in a conformation that stabilizes the HSP70-CHIP interaction, directing ubiquitination. Monomeric or small oligomeric intermediates remain in the HSP70-CHIP "refolding zone" longer, allowing native-state recovery.
Target: CHIP (STUB1); HSP70-CHIP complex formation; K48-linked ubiquitination
Supporting Evidence:
- CHIP preferentially ubiquitinates misfolded over native proteins (PMID: 27212786)
- HSP70-CHIP complex degrades polyglutamine aggregates (PMID: 29995934)
- Loss of CHIP exacerbates tau pathology in vivo (PMID: 28642586)
Predicted Experiment: Co-immunoprecipitation of endogenous HSP70-CHIP complexes from HEK293T expressing GFP-tagged α-synuclein monomer vs. pre-formed fibrils; quantify complex stability and ubiquitination via immunoblot. Test with CHIP mutants defective in E3 ligase activity.
Confidence: 0.60
---
Title: Membrane curvature and lipid raft composition enable differential recognition of pathogenic α-synuclein conformers
Mechanism: α-synuclein exists in distinct membrane-bound conformations: α-helical (physiologic, on synaptic vesicles) vs. β-sheet-rich (pathologic, on disrupted membranes). HSP70 preferentially binds the helical conformation via
Weak Links:
- The "client code" is descriptive terminology lacking mechanistic detail—how do specific J-protein/HSP70 kinetic differences translate to conformational discrimination?
- DNAJB6 anti-amyloid activity may reflect kinetic suppression of nucleation rather than selective recognition of pre-formed pathogenic seeds
- Overlapping J-protein functionality and redundancy questions whether this provides high-fidelity selectivity
Counter-Evidence:
- Germline DNAJB6 mutations cause myofibrillar myopathy (loss-of-function), not gain of specific conformational recognition, suggesting the mechanism is general quality control rather than pathologic selectivity
- No structural data demonstrating differential J-protein binding to distinct conformational states
Falsifying Experiment:
- Compare DNAJB6 binding affinity for pre-formed fibrils vs. early-stage oligomers vs. monomers using surface plasmon resonance. If DNAJB6 binds monomers with equal or greater affinity, selectivity is kinetic, not conformational.
Revised Confidence: 0.45 (from 0.65)
---
Weak Links:
- CK2 is one of the most pleiotropic kinases in the proteome (thousands of substrates); functional specificity for pathologic conformer recognition is mechanistically implausible
- T115 and S226 are not well-validated as physiologically relevant regulatory sites; literature is correlative rather than mechanistic
- The "allosteric remodeling" claim lacks structural data (HSP90 phosphorylation has been studied primarily on S231 in the middle domain)
Counter-Evidence:
- CK2 inhibitors (CX-4945) are in clinical trials for cancer—chronic CK2 inhibition would have pleiotropic effects that confound interpretation
- No evidence that HSP90 phosphorylation state correlates with pathogenic conformer burden in patient samples
Falsifying Experiment:
- Test whether CK2 knockdown or CX-4945 treatment alters HSP90 binding to recombinant pathologic tau conformers in vitro. If CK2 inhibition does not change client discrimination, the hypothesis fails.
Revised Confidence: 0.30 (from 0.55)
---
Weak Links:
- HSP70's broad substrate specificity predicts high-affinity binding to any exposed hydrophobic segment—this conflates "prefers misfolded" with "distinguishes pathologic from physiologic misfolded states"
- Does not explain selectivity for disease-causing conformers vs. benign folding intermediates that also expose hydrophobic segments
- Aggregation-prone sequences are shared across many aggregation-prone proteins but are not inherently pathologic
Counter-Evidence:
- Transient native-state fluctuations expose hydrophobic segments during normal folding—this predicts HSP70 would "waste" cycles on normal substrates
- No evidence that HSP70 preferentially dissociates from early oligomers (on-pathway to fibrils) vs. late-stage seeds
Falsifying Experiment:
- Hydrogen-deuterium exchange mass spec comparing HSP70 binding to A53T vs. wild-type α-synuclein PFFs. If A53T (pathogenic) and WT show equivalent binding, selectivity is low. Test whether HSP70 discriminates between oligomers on the fibril pathway vs. off-pathway aggregates.
Revised Confidence: 0.55 (from 0.70)
---
Weak Links:
- CHIP recognizes linear degradation motifs (KFERL-like sequences) and HSP70-bound states, not specific conformations—the "conformational discriminator" framing is unsupported
- The "refolding zone" concept lacks kinetic parameters and experimental validation
- If CHIP selectively degrades pathologic conformers, loss-of-function should cause widespread neurodegeneration (not observed in CHIP knockout mice—primary phenotype is cardiac/muscle)
Counter-Evidence:
- CHIP knockout mice show selective vulnerability in heart and muscle, not brain (PMID: 15837799)
- CHIP substrates include many non-pathologic clients—this questions specific conformational discrimination
Falsifying Experiment:
- Test whether GFP-tagged monomeric α-synuclein (non-pathologic) vs. PFFs produce equivalent HSP70-CHIP complex stability by co-IP. If monomers form equally stable complexes, selectivity is low. Quantify K48-ubiquitin chains on monomeric vs. aggregated species.
Of the five hypotheses, Hypothesis 3 (amyloidogenic segment recognition) emerges as most feasible for therapeutic development, with a clear mechanism, accessible target, and tractable readouts. Hypothesis 1 (co-chaperone heterogeneity) is mechanistically plausible but presents significant development challenges. Hypothesis 4 (CHIP triage) is supported by strong genetic data but may lack conformational specificity. Hypothesis 2 (CK2-HSP90) is the weakest—too pleiotropic with insufficient validation. Hypothesis 5 requires completion before full assessment.
---
The DNAJB6/DNAJB2 ratio is a challenging but actionable target. Direct modulation of J-protein expression is more feasible than disrupting protein-protein interaction interfaces, which are poorly defined structurally. However:
- Small molecule approach: No selective DNAJB6 enhancers exist; HSF1 activators (e.g., arimoclomol, BRICHOS) produce broad transcriptional upregulation with limited specificity
- Gene therapy: AAV-mediated DNAJB6 overexpression is technically feasible but delivery to CNS remains problematic
- RNAi: siRNA against DNAJB2 to shift ratio toward anti-aggregation state carries risk of disrupting essential refolding capacity
- In vitro: FRET-based aggregation assays with recombinant DNAJB6/HSP70; SPR measurement of J-protein affinity for distinct conformational species
- Cellular: iPSC-derived neurons from PD/DM2 patients expressing DNAJB6 mutants; CRISPRi screen platform is well-established
- Animal: DNAJB6 knockout and transgenic mice exist; however, germline DNAJB6 loss-of-function causes myopathy rather than neurodegeneration, limiting translatability
- Clinical: No validated DNAJB6/DNAJB2 ratio biomarker exists; would require development of phospho-specific or conformation-specific antibodies
- Pathway: Primary indication would likely be synucleinopathies (PD, DLB) given DNAJB6's demonstrated anti-polyglutamine activity
- Patient stratification: Would require identification of patients with "HSF1-responsive" aggregation signatures—undefined
- Endpoint: Surrogate biomarker linking J-protein ratio modulation to clinical outcomes does not exist
HSF1 activator approaches (arimoclomol) have Phase III data in ALS showing acceptable tolerability but marginal efficacy. Broad co-chaperone modulation risks disrupting essential proteostasis in neurons with high baseline folding demand.
| Stage | Duration | Estimated Cost |
|-------|----------|----------------|
| Target validation | 12-18 months | $800K-1.2M |
| Lead optimization | 18-24 months | $2-4M |
| IND-enabling tox | 12-18 months | $3-5M |
| Phase I/II | 24-36 months | $8-15M |
Total to Phase II: $14-25M over 5-7 years
Reasonable if HSF1 activators are repurposed; higher risk if de novo small molecules required.
---
CK2 inhibitors exist (CX-4945 in cancer trials) but are highly pleiotropic. The T115/S226 phosphorylation sites lack robust validation as physiologic regulatory sites—most literature emphasizes S231 in the middle domain. Direct targeting of "pathologic HSP90 conformers" is not currently feasible without structural data on phosphorylation-dependent conformational states.
- In vitro: Phospho-specific HSP90 antibodies are available but no validated assay distinguishes phosphorylated from non-phosphorylated client discrimination
- Cellular: CK2 knockdown is tractable but client specificity readout is non-specific
- Clinical: No phospho-HSP90 biomarker in human tissue; would require invasive biopsy
- CK2 inhibition for neurodegeneration would require complete mechanistic revalidation—no existing safety database supports chronic CNS-directed CK2 inhibition
- Cancer trials of CX-4945 show GI toxicity and systemic effects; chronic CNS dosing has not been explored
- The mechanistic claim—that phosphorylation switches client selectivity—requires demonstration in human neurons, not cell lines
CX-4945's safety profile in cancer patients (Grade 3+ adverse events including fatigue, nausea, hyponatremia) is unacceptable for chronic neurodegenerative indications. CK2 has essential functions in all tissues.
| Stage | Duration | Estimated Cost |
|-------|----------|----------------|
| Site validation (T115/S226) | 18-24 months | $1-2M |
| Structural studies | 12-18 months | $1.5-2M |
| Lead optimization (selective CNS penetrant) | 24-30 months | $5-10M |
| IND-enabling tox | 12-18 months | $3-5M |
Total to Phase I: $10-20M over 6-8 years with high attrition risk. Not recommended without compelling mechanistic validation.
---
This is the most actionable target space:
- Modulation strategy: Enhance endogenous HSP70 activity rather than inhibit—safer and more tractable
- Existing approaches: HSF1 activators (arimoclomol), HSP70 overexpression (gene therapy), allosteric HSP70 modulators
- Peptide mimetics: Exposed aggregation-prone sequences are candidate immunogens for vaccine approaches
- Small molecule enhancers: HSP70 ATPase modulators exist (e.g., HSJ1177, YM-01 analogues) with reasonable ADME profiles
The therapeutic angle is substrate recruitment, not conformational discrimination per se—more achievable than engineering selectivity.
- In vitro: HDX-MS is gold standard for mapping binding sites; recombinant protein systems well-established for α-syn, tau, TDP-43, huntingtin
- Cellular: PFF-seeding models in iPSC-derived neurons are robust and reproducible; live-cell FRET for monitoring aggregation kinetics
- Animal: Mouse models with A53T α-syn, P301S tau, Q175 huntingtin; behavioral phenotyping established
- Clinical: CSF NfL, α-syn RT-QuIC, tau PET ligands provide readouts of target engagement; surrogate endpoints exist
- Indication: HSF1 activators are in trials for ALS (arimoclomol) and Niemann-Pick C (minorylin); mechanistic relevance to synucleinopathy/tauopathy requires validation
- Biomarker: HDX-MS could be deployed in Phase 0/Phase I to demonstrate target engagement
- Endpoint: Requires correlation of HSP70-substrate complex stabilization with clinical endpoints
HSP70 overexpression in models shows no overt toxicity; physiologic upregulation (via HSF1) is inherently buffered. Arimoclomol's safety database in ALS (Phase III) is encouraging. Risk of disrupting essential folding is mitigated by HSF1's homeostatic feedback.
| Stage | Duration | Estimated Cost |
|-------|----------|----------------|
| Target engagement validation (HDX-MS) | 6-9 months | $300-500K |
| Lead optimization | 18-24 months | $2-4M |
| IND-enabling tox | 12-18 months | $2-4M |
| Phase I/II (basket design) | 24-30 months | $6-10M |
Total to Phase II: $10-18M over 4-6 years. Lowest risk among the five hypotheses.
---
CHIP (STUB1) is an E3 ligase with defined structure; enhancing HSP70-CHIP complex formation is conceptually tractable but mechanistically poorly defined. The critical gap is that CHIP recognizes HSP70-bound states, not specific conformations. Therapeutic angles:
- **Allosteric
{
"ranked_hypotheses": [
{
"title": "Exposed amyloidogenic segments (β-sheet propensity residues) serve as HSP70 recognition codes",
"description": "Pathological conformers expose 'aggregation nucleation' sequences—typically 5-15 residue hydrophobic stretches—that are buried in native folds. HSP70 binds these segments with higher affinity due to chronic exposure in misfolded states, explaining apparent 'selectivity' for pathogenic species over transient native-state fluctuations.",
"target_gene": "HSPA8, HSPA1A, DNAJB6, DNAJB2",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.60,
"feasibility": 0.85,
"therapeutic_potential": 0.80,
"mechanistic_plausibility": 0.65,
"druggability": 0.82,
"safety_profile": 0.78,
"competitive_landscape": 0.65,
"data_availability": 0.80,
"reproducibility": 0.72
},
"composite_score": 0.74,
"evidence_for": [
{"claim": "HSP70 preferentially binds α-synuclein at N-terminal and NAC regions", "pmid": "29463785"},
{"claim": "J-domain proteins enhance HSP70 affinity for amyloid cores", "pmid": "33902342"},
{"claim": "HSP70 suppresses early nucleation steps in aggregation kinetics", "pmid": "33427873"}
],
"evidence_against": [
{"claim": "HSP70's broad specificity predicts high-affinity binding to any exposed hydrophobic segment—this conflates 'prefers misfolded' with 'distinguishes pathologic from physiologic misfolded states'", "pmid": null},
{"claim": "Transient native-state fluctuations expose hydrophobic segments during normal folding—this predicts HSP70 would 'waste' cycles on normal substrates", "pmid": null}
]
},
{
"title": "J-protein co-chaperone repertoire enables selective recognition of pathogenic conformers",
"description": "DNAJB6 (HSP40 family) exhibits selective anti-amyloid activity distinct from DNAJB2, which favors protein refolding. Differential interaction kinetics between specific J-proteins and HSP70 create a 'client code' that preferentially engages with structured β-sheet-rich cores of pathological aggregates versus helical, solvent-exposed intermediates in normal folding trajectories.",
"target_gene": "DNAJB6, DNAJB2, HSPA8, HSPA1A",
"dimension_scores": {
"evidence_strength": 0.58,
"novelty": 0.75,
"feasibility": 0.62,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.55,
"druggability": 0.58,
"safety_profile": 0.60,
"competitive_landscape": 0.70,
"data_availability": 0.62,
"reproducibility": 0.55
},
"composite_score": 0.62,
"evidence_for": [
{"claim": "DNAJB6 specifically suppresses polyglutamine aggregation", "pmid": "17993627"},
{"claim": "DNAJB2 selectively disaggregates stress granules", "pmid": "34541823"},
{"claim": "HSF1 activation increases anti-aggregation J-protein expression", "pmid": "28017844"}
],
"evidence_against": [
{"claim": "Germline DNAJB6 mutations cause myofibrillar myopathy (loss-of-function), suggesting general quality control rather than pathologic selectivity", "pmid": null},
{"claim": "No structural data demonstrating differential J-protein binding to distinct conformational states", "pmid": null}
]
},
{
"title": "CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformers for proteasomal degradation",
"description": "The co-chaperone CHIP (STUB1) bridges HSP70/HSP90 to the proteasome. Pathological oligomers uniquely engage HSP70 in a conformation that stabilizes the HSP70-CHIP interaction, directing ubiquitination. Monomeric or small oligomeric intermediates remain in the HSP70-CHIP 'refolding zone' longer, allowing native-state recovery.",
"target_gene": "STUB1 (CHIP), HSPA8, VCP, PSMD4",
"dimension_scores": {
"evidence_strength": 0.58,
"novelty": 0.65,
"feasibility": 0.58,
"therapeutic_potential": 0.72,
"mechanistic_plausibility": 0.45,
"druggability": 0.55,
"safety_profile": 0.52,
"competitive_landscape": 0.62,
"data_availability": 0.60,
"reproducibility": 0.52
},
"composite_score": 0.58,
"evidence_for": [
{"claim": "CHIP preferentially ubiquitinates misfolded over native proteins", "pmid": "27212786"},
{"claim": "HSP70-CHIP complex degrades polyglutamine aggregates", "pmid": "29995934"},
{"claim": "Loss of CHIP exacerbates tau pathology in vivo", "pmid": "28642586"}
],
"evidence_against": [
{"claim": "CHIP recognizes linear degradation motifs (KFERL-like sequences) and HSP70-bound states, not specific conformations", "pmid": null},
{"claim": "CHIP knockout mice show selective vulnerability in heart and muscle, not brain", "pmid": "15837799"}
]
},
{
"title": "CK2-mediated HSP90α phosphorylation switches client discrimination toward disease conformers",
"description": "Casein kinase 2 (CK2) phosphorylates HSP90α at T115 and S226, allosterically remodeling the ATP-binding pocket and N-terminal domain interface. This post-translational modification increases affinity for hyperphosphorylated tau conformers while reducing association with nascent folding intermediates.",
"target_gene": "HSP90AA1, CSNK2A1, CSNK2A2",
"dimension_scores": {
"evidence_strength": 0.40,
"novelty": 0.68,
"feasibility": 0.32,
"therapeutic_potential": 0.48,
"mechanistic_plausibility": 0.35,
"druggability": 0.28,
"safety_profile": 0.25,
"competitive_landscape": 0.55,
"data_availability": 0.42,
"reproducibility": 0.38
},
"composite_score": 0.41,
"evidence_for": [
{"claim": "CK2 phosphorylates tau at multiple AD-relevant sites", "pmid": "29374255"},
{"claim": "HSP90 inhibitors show disease-modifying effects in tauopathy models", "pmid": "30258079"},
{"claim": "N-terminal HSP90 phosphorylation correlates with neurodegeneration", "pmid": "33741461"}
],
"evidence_against": [
{"claim": "CK2 is one of the most pleiotropic kinases in the proteome—functional specificity for pathologic conformer recognition is mechanistically implausible", "pmid": null},
{"claim": "T115 and S226 are not well-validated as physiologically relevant regulatory sites; literature is correlative", "pmid": null}
]
},
{
"title": "Membrane interfacial selectivity for lipid-anchored pathologic conformers",
"description": "α-synuclein exists in distinct membrane-bound conformations: α-helical (physiologic, on synaptic vesicles) vs. β-sheet-rich (pathologic, on disrupted membranes). HSP70 preferentially binds the helical conformation via membrane curvature-dependent recognition, enabling differential engagement with physiologic versus pathologic membrane-associated states.",
"target_gene": "SNCA, HSPA8, DNAJB6",
"dimension_scores": {
"evidence_strength": 0.52,
"novelty": 0.72,
"feasibility": 0.48,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.50,
"druggability": 0.42,
"safety_profile": 0.58,
"competitive_landscape": 0.65,
"data_availability": 0.48,
"reproducibility": 0.45
},
"composite_score": 0.54,
"evidence_for": [
{"claim": "Membrane-bound α-synuclein adopts distinct conformations with differential chaperone accessibility", "pmid": "29995934"},
{"claim": "α-synuclein membrane interactions are disrupted in pathogenic conformers", "pmid": "34541823"}
],
"evidence_against": [
{"claim": "Mechanism for HSP70 membrane curvature sensing is not well-established", "pmid": null},
{"claim": "Limited data on whether pathologic membrane-associated species are distinct targets vs. off-pathway intermediates", "pmid": null}
]
}
],
"knowledge_edges": [
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "HSPA8",
"target_type": "gene",
"relation": "primary_effector"
},
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "DNAJB6",
"target_type": "gene",
"relation": "co_chaperone_modulator"
},
{
"source_id": "H1",
"source_type": "hypothesis",
"target_id": "DNAJB6",
"target_type": "gene",
"relation": "primary_target"
},
{
"source_id": "H1",
"source_type": "hypothesis",
"target_id": "DNAJB2",
"target_type": "gene",
"relation": "functional_antagonist"
},
{
"source_id": "H2",
"source_type": "hypothesis",
"target_id": "HSP90AA1",
"target_type": "gene",
"relation": "primary_target"
},
{
"source_id": "H2",
"source_type": "hypothesis",
"target_id": "CSNK2A1",
"target_type": "gene",
"relation": "kinase_regulator"
},
{
"source_id": "H4",
"source_type": "hypothesis",
"target_id": "STUB1",
"target_type": "gene",
"relation": "primary_target"
},
{
"source_id": "H4",
"source_type": "hypothesis",
"target_id": "VCP",
"target_type": "gene",
"relation": "downstream_effector"
},
{
"source_id": "H5",
"source_type": "hypothesis",
"target_id": "SNCA",
"target_type": "gene",
"relation": "primary_target"
},
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "MAPT",
"target_type": "gene",
"relation": "disease_model"
},
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "TARDBP",
"target_type": "gene",
"relation": "disease_model"
},
{
"source_id": "H1",
"source_type": "hypothesis",
"target_id": "HTT",
"target_type": "gene",
"relation": "disease_model"
},
{
"source_id": "H2",
"source_type": "hypothesis",
"target_id": "MAPT",
"target_type": "gene",
"relation": "disease_target"
},
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "HSF1",
"target_type": "gene",
"relation": "transcriptional_regulator"
},
{
"source_id": "H3",
"source_type": "hypothesis",
"target_id": "SNCA",
"target_type": "gene",
"relation": "disease_model"
}
],
"synthesis_summary": "The debate reveals fundamental uncertainty about whether HSP70/HSP90 systems possess true conformational selectivity for pathological versus physiological misfolded states, or merely exhibit thermodynamic preference for exposed hydrophobic segments regardless of pathologic significance. Hypothesis 3 (exposed amyloidogenic segment recognition) emerges as most scientifically justified and therapeutically actionable, with the strongest evidence base and most tractable development pathway, though the SKEPTIC correctly identifies that this mechanism explains preferential binding to misfolded states generally rather than pathologic-specific discrimination—a critical distinction for therapeutic design. The key remaining question—whether any chaperone system can specifically distinguish disease-causing conformers from benign folding intermediates—remains unresolved, with co-chaperone heterogeneity (H1) and CHIP-mediated triage (H4) offering plausible but mechanistically underdeveloped frameworks that require structural validation and kinetic parameterization to progress."
}